The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd (The Biovac Institute) is a Public Private Partnership (PPP) between the South African Government and The Biovac Consortium. The aim of the partnership is to establish domestic production facilities in order to ensure the security and sustainability of vaccines supply to the South African as well as the greater Southern African region.

Whilst establishing this capacity, Biovac is supplying paediatric vaccines throughout South Africa and exports to the South African region as well.

The Biovac Institutes’ vision is to be a Centre of Excellence rooted in Africa for the development and manufacture of affordable quality vaccines for Africa and the developing world’s needs. The only human vaccine manufacturing facility in South Africa, The Biovac Institutes’ focus is on ensuring that the country has the required domestic capacity to respond to both local and regional vaccine needs.

The Biovac Institute: Vaccines Value Chain

The Biovac Institute currently distributes vaccines in the Expanded Programme in Immunisation (EPI) which protects against the following diseases:

• Tuberculosis
• Polio
• Tetanus
• Pertussis
• Diptheria
• Measels
• Pneumonia
• Rotavirus 
• Hepatitis B
• Haemophilus Influenza

The Biovac Institute is actively pursuing the local manufacture of vaccines against these diseases. This being achieved through its own Research and Development as well as Collaboration with emerging and established global multi-national manufacturing companies.
The Biovac Institute is based in Pinelands, Cape Town and employs over 100 staff in various aspects of manufacturing and support services.

For more info contact:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: www.biovac.co.za